SLC5A2 and diabetes mellitus: A subgroup analysis of the DAPA-HF indicated that dapagliflozin lowers the risk of cardiovascular deaths by 15% in patients without diabetes and 21% in patients with diabetes, providing evidence that the benefits of SGLT2 inhibition are not limited to people with diabetes.42